Amneal announces four new products

BRIDGEWATER, N.J. — Amneal Pharmaceuticals has introduced four new products since June.

The company received FDA approval on July 13 for its tobramycin inhalation solution, a generic equivalent for Tobi inhalation solution and the first inhalation solution formulation that the company offers.

“Tobramycin is extremely exciting for us in that it’s a new dosage form for Amneal—proof we’re delivering the varied portfolio we committed to offering our customers,” Amneal Co-CEO and Chairman Chirag Patel said.

Amneal also started shipping 5- and 10-mg tablets of memantine HCl immediate release tablets —  one of the first generic equivalents to Namenda on the market — on July 11. 

“We developed memantine at a customer’s request,” Patel said. “For some time, patients and payers have been eagerly awaiting availability of this generic product.”

In early June, Amneal introduced temozolomide capsules (AB-rated to Temodar) in six different strengths, in addition to divalproex sodium extended release (AB-rated to Depakote ER) in 250 mg and 500 mg tablets.